Subtype
Endocrine Carcinoma
CI-CAN-00000838Explore in graph →
574 active trials16 approved drugs58 evidence items
- NCIt
- C215715
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000838Explore in graph →
Clinical trials
1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (236)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications(POTENTIATE) | terminated | Phase 1 | 85 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 |
| Aug 13, 2026 |
| clinicaltrials |
| NCT05616624 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers | terminated | Phase 1 / Phase 2 | 31 | Washington University School of MedicineOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | terminated | Phase 1 / Phase 2 | 12 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05130255 | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | terminated | Phase 1 | 23 | Y-mAbs TherapeuticsINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05815160 | Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy | terminated | Phase 1 | 34 | Debiopharm International SAINDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT06939036 | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )(SANTANA-225) | terminated | Phase 1 / Phase 2 | 2 | Ariceum Therapeutics GmbHINDUSTRY | 2 | Feb 5, 2026 | clinicaltrials |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma(Spencer) | terminated | Phase 1 / Phase 2 | 70 | EnteromeINDUSTRY | 8 | Jan 30, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT03901573 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | terminated | Phase 1 / Phase 2 | 31 | NeoImmuneTechINDUSTRY | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06016270 | A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 10 | STCube, Inc.INDUSTRY | 2 | Sep 5, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT03469011 | A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. | terminated | Phase 1 | 14 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT04870112 | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer(SCope-D1) | terminated | Phase 1 | 18 | AstraZenecaINDUSTRY | 4 | Apr 17, 2025 | clinicaltrials |
| NCT04101357 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | terminated | Phase 1 / Phase 2 | 54 | BioNTech SEINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT05999292 | Phase 1 Study of 68Ga-R8760 | terminated | Phase 1 | 11 | Radionetics OncologyINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05049863 | Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) | terminated | Phase 1 | 17 | Washington University School of MedicineOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03879798 | DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05191797 | Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 3 | University of WashingtonOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT00791154 | QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer(SCLC) | terminated | Phase 1 / Phase 2 | 213 | NantCell, Inc.INDUSTRY | 0 | Aug 23, 2024 | clinicaltrials |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | terminated | Phase 1 / Phase 2 | 41 | Turning Point Therapeutics, Inc.INDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT01898156 | Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer | terminated | Phase 1 / Phase 2 | 37 | Kyowa Kirin Korea Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04610658 | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | terminated | Phase 1 | 34 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03963414 | A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | terminated | Phase 1 | 1 | University of NebraskaOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT04750239 | Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer | terminated | Phase 1 / Phase 2 | 3 | Y-mAbs TherapeuticsINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 4 | Xencor, Inc.INDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | terminated | Phase 1 | 35 | Aileron Therapeutics, Inc.INDUSTRY | 7 | Oct 10, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 28 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Jul 12, 2022 | clinicaltrials |
| NCT04173325 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | terminated | Phase 1 | 10 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT02584829 | Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma | terminated | Phase 1 / Phase 2 | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT03387332 | APG-1252 in Patients With SCLC or Advanced Solid Tumors | terminated | Phase 1 | 24 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Aug 27, 2021 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials